Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05373823 · ClinicalTrials.gov registry record · NA

MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors

A NA study of Melanoma, sponsored by Rutgers, The State University of New Jersey.

Recruiting
Registry status
NA
Development phase
385
Enrollment target
1
Study location

NCT05373823 is a NA study of Melanoma that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 385 participants, below the 705-participant average among 266 other Melanoma trials with a reported enrollment target (45% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05373823, a NA study of Melanoma, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.

RECRUITING
Registry status
NA
Development phase
385 participants
Enrollment target
1
Study location

Study Summary

This project, mySmartSkin (MSS), includes an innovative Type 1 hybrid effectiveness-implementation trial designed to enhance the effects of MSS and simultaneously assess key implementation outcomes (e.g., cost, adoption) as well as contextual factors important for scale-up in community and health care settings where melanoma survivors receive follow-up care. A type 1 hybrid effectiveness-implementation design allows us to engage multilevel stakeholders throughout this process, evaluate the effectiveness of the enhanced MSS, and identify critical factors for wide-scale implementation. Aim 1 will focus on enhancing the previous version of MSS by collaborating with multi-level stakeholders in qualitative interviews and usability testing. Aim 2 will evaluate the effects of enhanced MSS on thorough skin-self examinations (SSE) in a randomized-control trial (RCT) and examine its impact on the diagnosis of new/recurrent melanomas. Aim 3 will focus on assessing selected implementation outcomes and identify factors relevant to future scale-up for widespread dissemination and implementation.

Conditions Studied

Melanoma

Interventions

  • OTHER MySmartSkin enhancement
  • OTHER Educational webpage on Skin Self-Examination
  • OTHER Assess implementation outcomes

Study Locations (1)

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick

Trial Details

FieldValue
Enrollment Target 385 participants
Start Date 2023-03-06
Est. Completion 2027-03-31
Phase NA

Sponsor

Rutgers, The State University of New Jersey

413 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05373823

The ClinicalTrials.gov registry entry for NCT05373823 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 385 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 705-participant average among 266 other Melanoma trials with a reported enrollment target (45% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which MySmartSkin enhancement is the first listed.

NCT05373823 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT05373823 about?

NCT05373823 is a clinical study titled "MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors". This project, mySmartSkin (MSS), includes an innovative Type 1 hybrid effectiveness-implementation trial designed to enhance the effects of MSS and simultaneously assess key implementation outcomes (e.g., cost, adoption) as well as contextual factors important for scale-up in community and health ca...

What is the current status of trial NCT05373823?

This trial is currently recruiting. It is a NA study. The enrollment target is 385 participants. The study started on 2023-03-06. Estimated completion is 2027-03-31.

What conditions does trial NCT05373823 study?

This clinical trial studies the following conditions: Melanoma.

What interventions are being tested in trial NCT05373823?

The interventions under investigation include: MySmartSkin enhancement (OTHER), Educational webpage on Skin Self-Examination (OTHER), Assess implementation outcomes (OTHER).

Who is sponsoring clinical trial NCT05373823?

This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05373823 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

New Jersey

All trials with a study site in New Jersey

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.